Gilead plans to produce two mn remdesivir courses by 2020 end

Gilead Sciences Inc is planning to make more than two million courses of its potential COVID-19 drug remdesivir by the end of the year and start trials of an easier-to-use inhaled version in August, the company said on Monday. Continue Reading